

Hereditary Angioedema Therapeutics Market - 2022

<https://marketpublishers.com/r/H1F709F36196EN.html>

Date: November 2025

Pages: 200

Price: US\$ 2,999.00 (Single User License)

ID: H1F709F36196EN

Abstracts

The Hereditary Angioedema Therapeutics Market was valued at USD 2.9 billion in 2022 and is anticipated to reach by , at a CAGR of 0.086 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Hereditary Angioedema Therapeutics Market.

This report delivers a comprehensive overview of the Hereditary Angioedema Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hereditary Angioedema Therapeutics Market. The Hereditary Angioedema Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–.

Hereditary Angioedema Therapeutics Market Scope:

By Drug Type

Kallikrein Inhibitor

C1 Esterase Inhibitor

Selective Bradykinin B2 Receptor Antagonist

Others

By Treatment Type

On-demand

Prophylaxis

By Route of Administration

Intravenous

Subcutaneous

Oral

Key Players

BioCryst Pharmaceuticals, Inc

CSL Behring LLC

Takeda Pharmaceutical Company

Pharming Healthcare, Inc

Sanofi

Attune Pharmaceuticals, Inc

Ionis Pharmaceuticals

KalVista Pharmaceuticals, Inc

Arrowhead Pharmaceuticals

Advanced Technology & Industrial Co., Ltd(LIST NOT EXHAUSTIVE)

Major Highlights

This report delivers a comprehensive overview of the Hereditary Angioedema Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hereditary Angioedema Therapeutics Market. The Hereditary Angioedema Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise

information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Drug Class
- 3.2. Snippet by Treatment Type
- 3.3. Snippet by Route of Administration
- 3.4. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. The Increasing Prevalence of Hereditary Angioedema
 - 4.1.1.2. The Increasing Support from Non-profit organizations
 - 4.1.2. Restraints
 - 4.1.2.1. High Cost of Treatment
 - 4.1.3. Opportunity
 - 4.1.3.1. The High Cost of Treatment will Hamper the Growth of the Market
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis

6. COVID-19 ANALYSIS

- 6.1. Analysis of COVID-19
 - 6.1.1. Scenario Before COVID-19

- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion

7. BY DRUG TYPE

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 7.1.2. Market Attractiveness Index, By Drug Class
- 7.2. Kallikrein Inhibitor*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. C1 Esterase Inhibitor
- 7.4. Selective Bradykinin B2 Receptor Antagonist
- 7.5. Others

8. BY TREATMENT TYPE

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
 - 8.1.2. Market Attractiveness Index, By Treatment Type
- 8.2. On-demand*
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Prophylaxis

9. BY ROUTE OF ADMINISTRATION

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 9.1.2. Market Attractiveness Index, By Route of Administration
- 9.2. Intravenous*
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

9.3. Subcutaneous

9.4. Oral

10. BY REGION

10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

10.1.2. Market Attractiveness Index, By Region

10.2. North America

10.2.1. Introduction

10.2.2. Key Region-Specific Dynamics

10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.2.6.1. The U.S.

10.2.6.2. Canada

10.2.6.3. Mexico

10.3. Europe

10.3.1. Introduction

10.3.2. Key Region-Specific Dynamics

10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.3.6.1. Germany

10.3.6.2. The U.K.

10.3.6.3. France

10.3.6.4. Spain

10.3.6.5. Italy

10.3.6.6. Rest of Europe

10.4. South America

10.4.1. Introduction

10.4.2. Key Region-Specific Dynamics

10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.4.6.1. Brazil

10.4.6.2. Argentina

10.4.6.3. Rest of South America

10.5. Asia-Pacific

10.5.1. Introduction

10.5.2. Key Region-Specific Dynamics

10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.5.6.1. China

10.5.6.2. India

10.5.6.3. Japa

10.5.6.4. Australia

10.5.6.5. Rest of Asia-Pacific

10.6. Middle East and Africa

10.6.1. Introduction

10.6.2. Key Region-Specific Dynamics

10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

11. COMPETITIVE LANDSCAPE

11.1. Competitive Scenario

11.2. Market Positioning/Share Analysis

11.3. Mergers and Acquisitions Analysis

12. COMPANY PROFILES

12.1. BioCryst Pharmaceuticals, Inc*

12.1.1. Company Overview

12.1.2. Product Portfolio and Description

12.1.3. Financial Overview

12.1.4. Key Developments

- 12.2. CSL Behring LLC
- 12.3. Takeda Pharmaceutical Company
- 12.4. Pharming Healthcare, Inc
- 12.5. Sanofi
- 12.6. Attune Pharmaceuticals, Inc
- 12.7. Ionis Pharmaceuticals
- 12.8. KalVista Pharmaceuticals, Inc
- 12.9. Arrowhead Pharmaceuticals
- 12.10. Advanced Technology & Industrial Co., Ltd(*LIST NOT EXHAUSTIVE)

13. APPENDIX

- 13.1. About Us and Services
- 13.2. Contact Us

I would like to order

Product name: Hereditary Angioedema Therapeutics Market - 2022

Product link: <https://marketpublishers.com/r/H1F709F36196EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H1F709F36196EN.html>